Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ixico secures new contract with US-based client

(Sharecast News) - Neuroscience imaging firm Ixico has signed a contract with a new US-based client to provide imaging services for a Phase 2 Huntington's Disease clinical trial. Ixico said on Tuesday that the contract value, which will be delivered over approximately two and a half years, was worth more than £500,000 to the company.

The AIM-listed firm added that the contract award reinforced its "sustained positive commercial momentum" and aligns with its strategic pillars to drive expansion and growth.

Chief executie Bram Goorden said: "We are delighted to announce our involvement in this Phase 2 clinical trial, which aims to address the urgent need for effective treatments for Huntington's disease.

"This contract further demonstrates Ixico's expertise in supporting neurodegenerative disease trials, reinforcing our role as a trusted partner for sponsors."

As of 1045 GMT, Ixico shares were up 0.093% at 10.76p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Catenai extends convertible loan note facility with Klarian
(Sharecast News) - Digital media and technology specialist Catenai announced an extension to the redemption date of its £0.45m unsecured convertible loan note (CLN) facility with Klarian on Monday.
Eden Research revenue rises, losses set to widen
(Sharecast News) - Sustainable biopesticide and biocontrol technology specialist Eden Research reported significant revenue growth for the year ended 31 December on Monday, alongside a positive outlook for 2025.
Science Group set for another record adjusted operating profit
(Sharecast News) - Science Group said in an update on Monday that trading for the year ended 31 December was expected to deliver another record year of adjusted operating profit, in line with or slightly exceeding board expectations.
hVIVO completes pilot study for hMPV challenge model
(Sharecast News) - Contract research organisation and human challenge trial specialist hVIVO announced the successful completion of a pilot characterisation study for its human metapneumovirus (hMPV) challenge model on Monday.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.